ENDO 2025. Older adults, rural populations, and residents in the Midwest experienced the highest mortality rates, according to new data.

GSK's RSV vaccine Arexvy would join shots from Pfizer and Moderna for the younger adult population, broadening choice for those with risk factors for severe disease.

FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.

Baxdrostat met the primary and all secondary endpoints, setting up a first regulatory filing for the selective aldosterone synthase inhibitor, according to AstraZeneca.

Treatment should address root causes, including lifestyle modifications, stress management, and gut health, Monu Khanna, MD, told Patient Care.

The abrupt cancellation, without warning or cause, has medical groups and health care leaders concerned about patient access to no-cost preventive services.

Key predictors of the severity of self-reported cognitive complaints among nurses going through menopause included symptom severity and climacteric stage.

Bayer's elinzanetant gains UK approval as the first dual-action, nonhormonal treatment for menopausal symptoms.

Lifestyle medicine integrates a spectrum of therapeutic lifestyle interventions best delivered by specialists who are often available to create a "virtual" team.

These new FDA-approved drugs include treatments for migraine, chronic spontaneous urticaria, RSV, and more.

Verekitug is the only biologic in development for COPD that targets the TSLP receptor directly.

Tralokinumab met key trial endpoints with no new safety signals in treatment of moderate-to-severe hand eczema, in adults who are candidates for systemic therapy.

Dr Khanna breaks down the bidirectional relationship and explains why standard pain management often falls short for people with obesity.

A recent study highlights the importance of medication adherence for significant weight loss and improved glycemic control in obesity treatment with GLP-1 agonists.

The adult vaccine market is poised for explosive growth, with more than 100 product launches expected over the next 10 years. Are US clinicians ready?

Moderna’s Spikevax receives full FDA approval for use in children at increased risk for COVID-19, expanding protection ahead of the 2025–2026 virus season.

TSND-201, a rapid-acting neuroplastogen, demonstrated statistically significant symptom improvement by day 10, which was durable throughout the study until Day 64.

Richard Rosenfeld, MD, MPH, MBA, lead author of new guidelines on sustained lifestyle change as central to treating, even reversing T2D, answers the question.

Monu Khanna, MD, discusses common medications, non-drug strategies, and holistic approaches to improve outcomes.

The adjusted dosing for donanemab in early AD reduced ARIA-E risk by 41% compared to the original dosing, without compromising efficacy.